Alkermes plc. Deferred Income Tax Assets, Net
Alkermes plc. (ALKS) had Deferred Income Tax Assets, Net of $123.04 million as of 2026-06-30, per its 10-Q filed 2026-07-28.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:DeferredIncomeTaxAssetsNet · last filed 2026-07-28
- 2026-06-30: Deferred Income Tax Assets, Net $123.04M.
- 2026-03-31: Deferred Income Tax Assets, Net $134.81M.
- 2025-12-31: Deferred Income Tax Assets, Net $125.81M.
- 2025-09-30: Deferred Income Tax Assets, Net $130.34M.
| Period end | Deferred Income Tax Assets, Net | Deferred Income Tax Assets, Net as first filed |
|---|---|---|
| 2026-06-30 | $123.04M 10-Q · filed 2026-07-28 | |
| 2026-03-31 | $134.81M 10-Q · filed 2026-05-05 | |
| 2025-12-31 | $125.81M 10-Q · filed 2026-07-28 | |
| 2025-09-30 | $130.34M 10-Q · filed 2025-10-28 | |
| 2025-06-30 | $155.53M 10-Q · filed 2025-07-29 | |
| 2025-03-31 | $152.14M 10-Q · filed 2025-05-01 | |
| 2024-12-31 | $154.84M 10-K · filed 2026-02-25 | |
| 2024-09-30 | $159.96M 10-Q · filed 2024-10-24 | |
| 2024-06-30 | $167.38M 10-Q · filed 2024-07-24 | |
| 2024-03-31 | $182.54M 10-Q · filed 2024-05-01 | |
| 2023-12-31 | $195.89M 10-K · filed 2025-02-12 | |
| 2023-09-30 | $162.18M 10-Q · filed 2023-10-25 | |
| 2023-06-30 | $153.15M 10-Q · filed 2023-07-26 | |
| 2023-03-31 | $151.23M 10-Q · filed 2023-04-26 | |
| 2022-12-31 | $114.57M 10-K · filed 2024-02-21 | $115.60M 10-K · filed 2023-02-16 |
| 2022-09-30 | $137.15M 10-Q · filed 2022-11-02 | |
| 2022-06-30 | $123.70M 10-Q · filed 2022-07-27 | |
| 2022-03-31 | $112.52M 10-Q · filed 2022-04-27 | |
| 2021-12-31 | $81.83M 10-K · filed 2023-02-16 | |
| 2021-09-30 | $84.50M 10-Q · filed 2021-10-27 | |
| 2021-06-30 | $75.64M 10-Q · filed 2021-07-28 | |
| 2021-03-31 | $81.12M 10-Q · filed 2021-04-28 | |
| 2020-12-31 | $86.23M 10-K · filed 2022-02-16 | |
| 2020-09-30 | $86.34M 10-Q · filed 2020-10-29 | |
| 2020-06-30 | $88.45M 10-Q · filed 2020-07-29 | |
| 2019-12-31 | $96.56M 10-K · filed 2021-02-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |